Unknown PHASE4 INTERVENTIONAL 3-arm NCT01028326

PCV10 Reactogenicity and Immunogenicity Study - Malindi (PRISM)

Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months

Sponsor: GlaxoSmithKline

Interventions PCV10 and DTaP hepatitis A vaccine, DTaP, PCV10

Updated 6 times since 2017 Last updated: Feb 22, 2018 Started: Jan 31, 2010 Primary completion: Sep 30, 2010 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pneumococcal Pneumonia, this trial is ongoing. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Aug 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Aug 2019 [monthly]

Active Not Recruiting PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE4

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
KEMRI-Wellcome Trust Collaborative Research Program
Kenya Ministry of Health
University of Colorado, Denver
University of Oxford

Data source: KEMRI-Wellcome Trust Collaborative Research Program

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Malindi, Kenya